Fidaxomicin versus Vancomycin for <i>Clostridium difficile</i> InfectionThomas Louie, Youe‐Kong Shue|New England Journal of Medicine|2011Cited by 1.6k
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Paul Feuerstadt, Gary P. Wang et al.|Drugs|2022Cited by 273
Hypoxia-Inducible Factor Signaling Provides Protection in Clostridium difficile-Induced Intestinal InjurySimon A. Hirota, Paul L. Beck, Kyla Fines et al.|Gastroenterology|2010Cited by 102
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Paul Feuerstadt, Maha Assi et al.|Drugs|2022Cited by 6